A drug safety evaluation of rituximab and risk of hepatitis B.
about
Association of Lymphomagenesis and the Reactivation of Hepatitis B Virus in Non-Hodgkin LymphomaOptimizing antiviral agents for hepatitis B management in malignant lymphomas.Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Nonintervention
P2860
A drug safety evaluation of rituximab and risk of hepatitis B.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
A drug safety evaluation of rituximab and risk of hepatitis B.
@en
type
label
A drug safety evaluation of rituximab and risk of hepatitis B.
@en
prefLabel
A drug safety evaluation of rituximab and risk of hepatitis B.
@en
P2860
P1476
A drug safety evaluation of rituximab and risk of hepatitis B.
@en
P2093
Kenneth R Carson
Peter Riedell
P2860
P304
P356
10.1517/14740338.2014.918948
P407
P577
2014-05-12T00:00:00Z